We are Reactec.
We help forward-thinking organisations switch from being mitigators of industrial workplace health risk, to being preventers.
We call it prevention engineering.
Approaching old risks in a new way using an eco-system of workplace wearables
and cloud-based analytics. Armed with reliable data about what's happening on
the ground you can refine your methods and tailor controls faster.
Actively protect the health and wellbeing of your workers by engineering out risk.
We help forward-thinking organisations switch from being mitigators of industrial workplace health risk, to being preventers.
We call it prevention engineering.
Approaching old risks in a new way using an eco-system of workplace wearables
and cloud-based analytics. Armed with reliable data about what's happening on
the ground you can refine your methods and tailor controls faster.
Actively protect the health and wellbeing of your workers by engineering out risk.
Location: United Kingdom, Scotland, City of Edinburgh
Employees: 11-50
Total raised: $870.81K
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | Archangels | archangels... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.03.2017 | - | $870.81K | - |
Mentions in press and media 3
| Date | Title | Description |
| 03.11.2025 | Comment | Scotland’s Deep Tech Opportunity | Scotland has a longstanding reputation for punching above its weight when it comes to science and engineering – supported not only by our world-class academic institutions, but also a strong ecosystem of spin-outs and start-ups. This is par... |
| 18.08.2025 | Ideagen Acquires Reactec | Ideagen, a Ruddington, Nottingham, UK-based company which specializes in compliance and risk management software, acquired Reactec, an Edinburgh, Scotland, UK-based provider of a wearable technology with data analytics. The amount of the de... |
| 29.03.2017 | Reactec Closes £700k Funding | Reactec, an Edinburgh, United Kingdom-based provider of monitoring and management support solutions for hand and arm vibration syndrome (HAVS), completed a further £700k round of funding. The round, which included a £122k investment from Re... |